Dear All, The IDWeek 2024 program committee is again seeking programs on novel antimicrobial agents and novel diagnostics for presentation in pipeline sessions! Here’s what is sought: “Industry partners are invited to submit antimicrobials that are in preclinical stages of development (Phase II and III preferred) or recently approved after January 2024. “The pipeline sessions will include antibacterials, antifungals, and antivirals (excluding COVID-19 and HIV). “The

Dear All, I think it’s worth a newsletter to call your attention to several upcoming meetings. In addition to the 30 Aug CDC-FDA webinar on “Drug Development Considerations for the Prevention of Healthcare-Associated Infections” and PACCARB’s 12-13 Sep 2022 pandemic wargaming event, we have these 3 meetings. The first two just now hit my radar and

Dear All, As suggested by the subject line, this newsletter is a bit of a mish-mash of time-critical news about meetings and opportunities! The main thing is to look closely at the funding and meeting summaries below my signature for NEW items. Here are a few highlights: Do you recall IDSA’s scary 2004 hypothetical scenario